Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths worldwide and massive societal and economic burden. Recently, a new variant of SARS-CoV-2, known as B.1.1.7, was first detected in the United Kingdom and is...

Descripción completa

Detalles Bibliográficos
Autores principales: Reuschl, Ann-Kathrin, Thorne, Lucy G., Zuliani-Alvarez, Lorena, Bouhaddou, Mehdi, Obernier, Kirsten, Hiatt, Joseph, Soucheray, Margaret, Turner, Jane, Fabius, Jacqueline M., Nguyen, Gina T., Swaney, Danielle L., Rosales, Romel, White, Kris M., Avilés, Pablo, Kirby, Ilsa T., Melnyk, James E., Shi, Ying, Zhang, Ziyang, Shokat, Kevan M., García-Sastre, Adolfo, Jolly, Clare, Towers, Gregory J., Krogan, Nevan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836107/
https://www.ncbi.nlm.nih.gov/pubmed/33501437
http://dx.doi.org/10.1101/2021.01.24.427991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836107/
https://www.ncbi.nlm.nih.gov/pubmed/33501437
http://dx.doi.org/10.1101/2021.01.24.427991

Ejemplares similares